Brooklyn Investment Group Purchases New Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Brooklyn Investment Group acquired a new stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,149 shares of the company’s stock, valued at approximately $40,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its position in Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after acquiring an additional 297,500 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Poseida Therapeutics by 62.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock worth $1,027,000 after purchasing an additional 138,510 shares during the last quarter. Blair William & Co. IL grew its holdings in shares of Poseida Therapeutics by 14.1% during the second quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock worth $3,216,000 after purchasing an additional 136,273 shares during the last quarter. Fred Alger Management LLC acquired a new position in shares of Poseida Therapeutics in the third quarter valued at approximately $369,000. Finally, Advantage Alpha Capital Partners LP bought a new position in Poseida Therapeutics in the 3rd quarter valued at approximately $285,000. Institutional investors and hedge funds own 46.87% of the company’s stock.

Insider Activity

In related news, Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total transaction of $283,800.00. Following the transaction, the chairman now owns 651,291 shares in the company, valued at $6,161,212.86. The trade was a 4.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on PSTX shares. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Piper Sandler lowered Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 target price for the company. in a research report on Monday, December 2nd. Cantor Fitzgerald lowered Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 26th. HC Wainwright restated a “neutral” rating and set a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Finally, BTIG Research reiterated a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $9.50.

Poseida Therapeutics Stock Performance

Shares of PSTX opened at $9.50 on Monday. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. The firm’s fifty day simple moving average is $8.04 and its two-hundred day simple moving average is $4.71. Poseida Therapeutics, Inc. has a 12 month low of $1.87 and a 12 month high of $9.67. The stock has a market capitalization of $928.85 million, a P/E ratio of -15.08 and a beta of 1.63.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.